• Je něco špatně v tomto záznamu ?

European expert consensus statement on the systemic treatment of alopecia areata

L. Rudnicka, M. Arenbergerova, R. Grimalt, D. Ioannides, AC. Katoulis, E. Lazaridou, M. Olszewska, YS. Ovcharenko, BM. Piraccini, A. Prohic, A. Rakowska, P. Reygagne, MA. Richard, RO. Soares, M. Starace, S. Vañó-Galvan, A. Waskiel-Burnat

. 2024 ; 38 (4) : 687-694. [pub] 20240102

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24006596

Alopecia areata is an autoimmune form of non-scarring hair loss. It is usually characterized by limited areas of hair loss. However, the disease may progress to complete scalp and body hair loss (alopecia totalis, alopecia universalis). In patients with alopecia areata hair loss significantly impacts the quality of life. Children and adolescents with alopecia areata often experience bullying, including physical aggression. The disease severity evaluation tools used in clinical practice are: the Severity of Alopecia Tool (SALT) score and the Alopecia Areata Scale (AAS). A SALT score equal to or greater than 20 constitutes a commonly accepted indication for systemic therapy in alopecia areata. When using the AAS, moderate to severe alopecia areata should be considered a medical indication for systemic treatment. Currently, the only two EMA-approved medications for alopecia areata are baricitinib (JAK 1/2 inhibitor) for adults and ritlecitinib (JAK 3/TEC inhibitor) for individuals aged 12 and older. Both are EMA-approved for patients with severe alopecia areata. Other systemic medications used off-label in alopecia areata include glucocorticosteroids, cyclosporine, methotrexate and azathioprine. Oral minoxidil is considered an adjuvant therapy with limited data confirming its possible efficacy. This consensus statement is to outline a systemic treatment algorithm for alopecia areata, indications for systemic treatment, available therapeutic options, their efficacy and safety, as well as the duration of the therapy.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24006596
003      
CZ-PrNML
005      
20240423155359.0
007      
ta
008      
240412s2024 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/jdv.19768 $2 doi
035    __
$a (PubMed)38169088
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Rudnicka, L $u Department of Dermatology, Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000283081023
245    10
$a European expert consensus statement on the systemic treatment of alopecia areata / $c L. Rudnicka, M. Arenbergerova, R. Grimalt, D. Ioannides, AC. Katoulis, E. Lazaridou, M. Olszewska, YS. Ovcharenko, BM. Piraccini, A. Prohic, A. Rakowska, P. Reygagne, MA. Richard, RO. Soares, M. Starace, S. Vañó-Galvan, A. Waskiel-Burnat
520    9_
$a Alopecia areata is an autoimmune form of non-scarring hair loss. It is usually characterized by limited areas of hair loss. However, the disease may progress to complete scalp and body hair loss (alopecia totalis, alopecia universalis). In patients with alopecia areata hair loss significantly impacts the quality of life. Children and adolescents with alopecia areata often experience bullying, including physical aggression. The disease severity evaluation tools used in clinical practice are: the Severity of Alopecia Tool (SALT) score and the Alopecia Areata Scale (AAS). A SALT score equal to or greater than 20 constitutes a commonly accepted indication for systemic therapy in alopecia areata. When using the AAS, moderate to severe alopecia areata should be considered a medical indication for systemic treatment. Currently, the only two EMA-approved medications for alopecia areata are baricitinib (JAK 1/2 inhibitor) for adults and ritlecitinib (JAK 3/TEC inhibitor) for individuals aged 12 and older. Both are EMA-approved for patients with severe alopecia areata. Other systemic medications used off-label in alopecia areata include glucocorticosteroids, cyclosporine, methotrexate and azathioprine. Oral minoxidil is considered an adjuvant therapy with limited data confirming its possible efficacy. This consensus statement is to outline a systemic treatment algorithm for alopecia areata, indications for systemic treatment, available therapeutic options, their efficacy and safety, as well as the duration of the therapy.
650    _2
$a dospělí $7 D000328
650    _2
$a mladiství $7 D000293
650    _2
$a dítě $7 D002648
650    _2
$a lidé $7 D006801
650    12
$a alopecia areata $x farmakoterapie $7 D000506
650    _2
$a kvalita života $7 D011788
650    _2
$a alopecie $x farmakoterapie $7 D000505
650    _2
$a minoxidil $x terapeutické užití $7 D008914
650    _2
$a azathioprin $x terapeutické užití $7 D001379
650    12
$a inhibitory Janus kinas $x terapeutické užití $7 D000075242
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Arenbergerova, M $u Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Královské Vinohrady University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000279199619 $7 xx0074761
700    1_
$a Grimalt, R $u Universitat Internacional de Catalunya, Barcelona, Spain $1 https://orcid.org/0000000172048626 $7 xx0211554
700    1_
$a Ioannides, D $u 1st Department of Dermatology-Venereology, Aristotle University Medical School, Thessaloniki, Greece $1 https://orcid.org/0000000289979889
700    1_
$a Katoulis, A C $u 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, Greece $1 https://orcid.org/0000000181897486
700    1_
$a Lazaridou, E $u 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, Medical School, "Attikon" General University Hospital, Athens, Greece $1 https://orcid.org/0000000240723591
700    1_
$a Olszewska, M $u Department of Dermatology, Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000227448353
700    1_
$a Ovcharenko, Y S $u Department of Infectious Diseases and Clinical Immunology of the V.N. Karazin Kharkiv National University, Kharkiv, Ukraine $1 https://orcid.org/0000000224122251
700    1_
$a Piraccini, B M $u Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy $u Department of Medical and Surgical Sciences University of Bologna, Italy School of Specialization Dermatology and Venereology, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy $1 https://orcid.org/0000000165379689
700    1_
$a Prohic, A $u Department of Dermatovenerology, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina $1 https://orcid.org/0000000342276921
700    1_
$a Rakowska, A $u Department of Dermatology, Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000161173704
700    1_
$a Reygagne, P $u Centre de Santé Sabouraud, Hopital Saint Louis, Paris, France $1 https://orcid.org/0000000260622122
700    1_
$a Richard, M A $u CEReSS-EA 3279, Research Centrer in Health Services and Quality of Life Aix Marseille University, Dermatology Department, Universitary Hospital Timone, Assistance Publique Hôpitaux de Marseille, APHM, Marseille, France $1 https://orcid.org/0000000208709132
700    1_
$a Soares, R O $u CUF Descobertas Hospital, Lisbon, Portugal
700    1_
$a Starace, M $u Dermatology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy $u Department of Medical and Surgical Sciences University of Bologna, Italy School of Specialization Dermatology and Venereology, Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy $1 https://orcid.org/0000000239811527
700    1_
$a Vañó-Galvan, S $u Department Ramon y Cajal Hospital, IRYCIS, Grupo Pedro Jaén Clinic, TricoHRC Research Group, University of Alcala, Madrid, Spain $1 https://orcid.org/0000000327737494
700    1_
$a Waskiel-Burnat, A $u Department of Dermatology, Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000349843589
773    0_
$w MED00002983 $t Journal of the European Academy of Dermatology and Venereology $x 1468-3083 $g Roč. 38, č. 4 (2024), s. 687-694
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38169088 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155356 $b ABA008
999    __
$a ok $b bmc $g 2080914 $s 1216363
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 38 $c 4 $d 687-694 $e 20240102 $i 1468-3083 $m Journal of the European Academy of Dermatology and Venereology $n J Eur Acad Dermatol Venerol $x MED00002983
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace